Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/5346
Title: | Treatment of blastic phase chronic myeloid leukemia with mitoxantrone, cytosine arabinoside and high dose methylprednisolone | Authors: | Bolaman, Z. Köseoglu, M. Ayyildiz, O. Kadiköylü, G. Sönmez, H.M. Demir, S. Müftuüoglu, E. |
Keywords: | Blastic phase Chronic myelogenous leukemia High dose methylprednisolone 5 aza 2' deoxycytidine alpha interferon azacitidine carboplatin cladribine cytarabine etoposide fludarabine granulocyte colony stimulating factor hydroxyurea imatinib meprednisone mitoxantrone prednisolone vincristine adult age distribution article bacteremia blast cell crisis bone marrow hypoplasia cause of death chronic myeloid leukemia clinical article clinical trial conjunctivitis controlled clinical trial controlled study diarrhea dose response drug megadose drug tolerability febrile neutropenia female fever flushing human leukemia remission leukopenia liver dysfunction lung toxicity male mucosa inflammation nausea and vomiting neurotoxicity Philadelphia 1 chromosome pneumonia prognosis rash Streptococcus infection survival time validation process Adult Antineoplastic Combined Chemotherapy Protocols Blast Crisis Cytarabine Female Humans Leukemia, Myeloid, Chronic Male Methylprednisolone Middle Aged Mitoxantrone Remission Induction Survival Analysis Treatment Outcome |
Abstract: | Fourteen patients with blastic phase chronic myelogenous leukemia received combination chemotherapy with mitoxantrone 5 mg/m2 intravenously daily for 3 days, cytosine arabinoside 100 mg/m2 intravenously over 2 hours bid for 7 days and high dose methylprednisolone 1000 mg/day intravenously for 5 days. The patients' mean age was 52 ± 10 (range 34-64) and Philadelphia chromosome was positive in all. Five patients (35%) achieved complete remission and four patients (28%) had a partial remission. Overall remission rate was 64%. The mean survival was 11.1 ± 8.6 months (median 13) for all patients, 19.4 ± 4.0 months (median 19) for those achieving a complete remission, 12.50 ± 5.7 months (median 14) for patients with partial remission and 1.8 ± 1.8 months (median 2) for the unresponsive patients. Two of 5 unresponsive patients died early after the second course of remission induction. The treatment regimen was generally well tolerated. Marrow hypoplasia was observed in 9 (64%) patients and 7 (50%) had febrile episodes. Non-myelosupressive toxicity of the regimen was acceptable. Nausea and vomiting were observed in 8 (57%) patients and 3 (21%) patients developed flushing due to cytosine arabinoside. These results suggest that the regimen with mitoxantrone, cytosine arabinoside and high dose methylprednisolone in remission-induction of blastic phase chronic myelogenous leukemia may be a valid option that may also improve overall prognosis. | URI: | https://hdl.handle.net/11499/5346 https://doi.org/10.1163/156855902760262763 |
ISSN: | 0017-6559 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Show full item record
CORE Recommender
SCOPUSTM
Citations
3
checked on Nov 30, 2024
WEB OF SCIENCETM
Citations
1
checked on Dec 5, 2024
Page view(s)
40
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.